Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity: Bagsværd, Denmark Monday, January 27, 2025, 13:00
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
The yearlong downtrend in obesity drug supplier Novo Nordisk (NVO) is potentially over. Last Friday, Jan. 25, NVO stock gained 8.47% to close at $87.97. The company posted the results of its obesity ...
Here are some of the major companies whose stocks moved on the week’s news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback